CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
3.7.Patent Landscape
CHAPTER 4: SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Hydroxyurea
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.2.4 Hydroxyurea Sickle Cell Disease Treatment Market by Distribution Channel
4.2.4.1 Hospitals Pharmacies Market size and forecast, by region
4.2.4.2 Drug Stores and Retail Pharmacies Market size and forecast, by region
4.2.4.3 Online Providers Market size and forecast, by region
4.3 Oxybryta
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Adakveo
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 Others
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
CHAPTER 5: SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE
5.1 Overview
5.1.1 Market size and forecast
5.2 Sickle Cell Anemia
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 HbSC
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Others
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
CHAPTER 6: SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
6.1 Overview
6.1.1 Market size and forecast
6.2 Oral
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Parenteral
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
CHAPTER 7: SICKLE CELL DISEASE TREATMENT MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Drug Type
7.2.2.1 North America Hydroxyurea Sickle Cell Disease Treatment Market by Distribution Channel
7.2.3 North America Market size and forecast, by Type
7.2.4 North America Market size and forecast, by Route of Administration
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Drug Type
7.2.5.1.2 Market size and forecast, by Type
7.2.5.1.3 Market size and forecast, by Route of Administration
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Drug Type
7.2.5.2.2 Market size and forecast, by Type
7.2.5.2.3 Market size and forecast, by Route of Administration
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Drug Type
7.2.5.3.2 Market size and forecast, by Type
7.2.5.3.3 Market size and forecast, by Route of Administration
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Drug Type
7.3.2.1 Europe Hydroxyurea Sickle Cell Disease Treatment Market by Distribution Channel
7.3.3 Europe Market size and forecast, by Type
7.3.4 Europe Market size and forecast, by Route of Administration
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Drug Type
7.3.5.1.2 Market size and forecast, by Type
7.3.5.1.3 Market size and forecast, by Route of Administration
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Drug Type
7.3.5.2.2 Market size and forecast, by Type
7.3.5.2.3 Market size and forecast, by Route of Administration
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Drug Type
7.3.5.3.2 Market size and forecast, by Type
7.3.5.3.3 Market size and forecast, by Route of Administration
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Drug Type
7.3.5.4.2 Market size and forecast, by Type
7.3.5.4.3 Market size and forecast, by Route of Administration
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Drug Type
7.3.5.5.2 Market size and forecast, by Type
7.3.5.5.3 Market size and forecast, by Route of Administration
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Drug Type
7.3.5.6.2 Market size and forecast, by Type
7.3.5.6.3 Market size and forecast, by Route of Administration
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Drug Type
7.4.2.1 Asia-Pacific Hydroxyurea Sickle Cell Disease Treatment Market by Distribution Channel
7.4.3 Asia-Pacific Market size and forecast, by Type
7.4.4 Asia-Pacific Market size and forecast, by Route of Administration
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Drug Type
7.4.5.1.2 Market size and forecast, by Type
7.4.5.1.3 Market size and forecast, by Route of Administration
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Drug Type
7.4.5.2.2 Market size and forecast, by Type
7.4.5.2.3 Market size and forecast, by Route of Administration
7.4.5.3 India
7.4.5.3.1 Market size and forecast, by Drug Type
7.4.5.3.2 Market size and forecast, by Type
7.4.5.3.3 Market size and forecast, by Route of Administration
7.4.5.4 Australia
7.4.5.4.1 Market size and forecast, by Drug Type
7.4.5.4.2 Market size and forecast, by Type
7.4.5.4.3 Market size and forecast, by Route of Administration
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Drug Type
7.4.5.5.2 Market size and forecast, by Type
7.4.5.5.3 Market size and forecast, by Route of Administration
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Drug Type
7.4.5.6.2 Market size and forecast, by Type
7.4.5.6.3 Market size and forecast, by Route of Administration
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Drug Type
7.5.2.1 LAMEA Hydroxyurea Sickle Cell Disease Treatment Market by Distribution Channel
7.5.3 LAMEA Market size and forecast, by Type
7.5.4 LAMEA Market size and forecast, by Route of Administration
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Drug Type
7.5.5.1.2 Market size and forecast, by Type
7.5.5.1.3 Market size and forecast, by Route of Administration
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Drug Type
7.5.5.2.2 Market size and forecast, by Type
7.5.5.2.3 Market size and forecast, by Route of Administration
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Drug Type
7.5.5.3.2 Market size and forecast, by Type
7.5.5.3.3 Market size and forecast, by Route of Administration
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Drug Type
7.5.5.4.2 Market size and forecast, by Type
7.5.5.4.3 Market size and forecast, by Route of Administration
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 Agios Pharmaceuticals
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Bristol-Myers Squibb
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 CRISPR Therapeutics
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 editas Medicine
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Emmaus Life Sciences, Inc.
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Global Blood Therapeutics, Inc.
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Medunic USA Inc.
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Novartis AG
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Novo Nordisk
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Vifor Pharma
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
TABLE 1. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 2. SICKLE CELL DISEASE TREATMENT MARKET, FOR HYDROXYUREA, BY REGION, 2021-2031 ($MILLION)
TABLE 3. SICKLE CELL DISEASE TREATMENT MARKET FOR HYDROXYUREA, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. GLOBAL HYDROXYUREA SICKLE CELL DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 5. SICKLE CELL DISEASE TREATMENT MARKET, FOR HOSPITALS PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 6. SICKLE CELL DISEASE TREATMENT MARKET, FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 7. SICKLE CELL DISEASE TREATMENT MARKET, FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
TABLE 8. SICKLE CELL DISEASE TREATMENT MARKET, FOR OXYBRYTA, BY REGION, 2021-2031 ($MILLION)
TABLE 9. SICKLE CELL DISEASE TREATMENT MARKET FOR OXYBRYTA, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 10. SICKLE CELL DISEASE TREATMENT MARKET, FOR ADAKVEO, BY REGION, 2021-2031 ($MILLION)
TABLE 11. SICKLE CELL DISEASE TREATMENT MARKET FOR ADAKVEO, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 12. SICKLE CELL DISEASE TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 13. SICKLE CELL DISEASE TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 14. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 15. SICKLE CELL DISEASE TREATMENT MARKET, FOR SICKLE CELL ANEMIA, BY REGION, 2021-2031 ($MILLION)
TABLE 16. SICKLE CELL DISEASE TREATMENT MARKET FOR SICKLE CELL ANEMIA, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 17. SICKLE CELL DISEASE TREATMENT MARKET, FOR HBSC, BY REGION, 2021-2031 ($MILLION)
TABLE 18. SICKLE CELL DISEASE TREATMENT MARKET FOR HBSC, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 19. SICKLE CELL DISEASE TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 20. SICKLE CELL DISEASE TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 21. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 22. SICKLE CELL DISEASE TREATMENT MARKET, FOR ORAL, BY REGION, 2021-2031 ($MILLION)
TABLE 23. SICKLE CELL DISEASE TREATMENT MARKET FOR ORAL, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 24. SICKLE CELL DISEASE TREATMENT MARKET, FOR PARENTERAL, BY REGION, 2021-2031 ($MILLION)
TABLE 25. SICKLE CELL DISEASE TREATMENT MARKET FOR PARENTERAL, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 26. SICKLE CELL DISEASE TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 27. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 28. NORTH AMERICA HYDROXYUREA SICKLE CELL DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 29. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 30. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 31. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 32. U.S. SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 33. U.S. SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 34. U.S. SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 35. CANADA SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 36. CANADA SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 37. CANADA SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 38. MEXICO SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 39. MEXICO SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 40. MEXICO SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 41. EUROPE SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 42. EUROPE HYDROXYUREA SICKLE CELL DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 43. EUROPE SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 44. EUROPE SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 45. EUROPE SICKLE CELL DISEASE TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 46. GERMANY SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 47. GERMANY SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 48. GERMANY SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 49. FRANCE SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 50. FRANCE SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 51. FRANCE SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 52. UK SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 53. UK SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 54. UK SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 55. ITALY SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 56. ITALY SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 57. ITALY SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 58. SPAIN SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 59. SPAIN SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 60. SPAIN SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 61. REST OF EUROPE SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 62. REST OF EUROPE SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 63. REST OF EUROPE SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 64. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 65. ASIA-PACIFIC HYDROXYUREA SICKLE CELL DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 66. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 67. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 68. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 69. JAPAN SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 70. JAPAN SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 71. JAPAN SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 72. CHINA SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 73. CHINA SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 74. CHINA SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 75. INDIA SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 76. INDIA SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 77. INDIA SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 78. AUSTRALIA SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 79. AUSTRALIA SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 80. AUSTRALIA SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 81. SOUTH KOREA SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 82. SOUTH KOREA SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 83. SOUTH KOREA SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 84. REST OF ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 85. REST OF ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 86. REST OF ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 87. LAMEA SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 88. LAMEA HYDROXYUREA SICKLE CELL DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 89. LAMEA SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 90. LAMEA SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 91. LAMEA SICKLE CELL DISEASE TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 92. BRAZIL SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 93. BRAZIL SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 94. BRAZIL SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 95. SAUDI ARABIA SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 96. SAUDI ARABIA SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 97. SAUDI ARABIA SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 98. SOUTH AFRICA SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 99. SOUTH AFRICA SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 100. SOUTH AFRICA SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 101. REST OF LAMEA SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 102. REST OF LAMEA SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 103. REST OF LAMEA SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 104.AGIOS PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 105.AGIOS PHARMACEUTICALS: OPERATING SEGMENTS
TABLE 106.AGIOS PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 107.AGIOS PHARMACEUTICALS: NET SALES,
TABLE 108.AGIOS PHARMACEUTICALS: KEY STRATERGIES
TABLE 109.BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 110.BRISTOL-MYERS SQUIBB: OPERATING SEGMENTS
TABLE 111.BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
TABLE 112.BRISTOL-MYERS SQUIBB: NET SALES,
TABLE 113.BRISTOL-MYERS SQUIBB: KEY STRATERGIES
TABLE 114.CRISPR THERAPEUTICS: COMPANY SNAPSHOT
TABLE 115.CRISPR THERAPEUTICS: OPERATING SEGMENTS
TABLE 116.CRISPR THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 117.CRISPR THERAPEUTICS: NET SALES,
TABLE 118.CRISPR THERAPEUTICS: KEY STRATERGIES
TABLE 119.EDITAS MEDICINE: COMPANY SNAPSHOT
TABLE 120.EDITAS MEDICINE: OPERATING SEGMENTS
TABLE 121.EDITAS MEDICINE: PRODUCT PORTFOLIO
TABLE 122.EDITAS MEDICINE: NET SALES,
TABLE 123.EDITAS MEDICINE: KEY STRATERGIES
TABLE 124.EMMAUS LIFE SCIENCES, INC.: COMPANY SNAPSHOT
TABLE 125.EMMAUS LIFE SCIENCES, INC.: OPERATING SEGMENTS
TABLE 126.EMMAUS LIFE SCIENCES, INC.: PRODUCT PORTFOLIO
TABLE 127.EMMAUS LIFE SCIENCES, INC.: NET SALES,
TABLE 128.EMMAUS LIFE SCIENCES, INC.: KEY STRATERGIES
TABLE 129.GLOBAL BLOOD THERAPEUTICS, INC.: COMPANY SNAPSHOT
TABLE 130.GLOBAL BLOOD THERAPEUTICS, INC.: OPERATING SEGMENTS
TABLE 131.GLOBAL BLOOD THERAPEUTICS, INC.: PRODUCT PORTFOLIO
TABLE 132.GLOBAL BLOOD THERAPEUTICS, INC.: NET SALES,
TABLE 133.GLOBAL BLOOD THERAPEUTICS, INC.: KEY STRATERGIES
TABLE 134.MEDUNIC USA INC.: COMPANY SNAPSHOT
TABLE 135.MEDUNIC USA INC.: OPERATING SEGMENTS
TABLE 136.MEDUNIC USA INC.: PRODUCT PORTFOLIO
TABLE 137.MEDUNIC USA INC.: NET SALES,
TABLE 138.MEDUNIC USA INC.: KEY STRATERGIES
TABLE 139.NOVARTIS AG: COMPANY SNAPSHOT
TABLE 140.NOVARTIS AG: OPERATING SEGMENTS
TABLE 141.NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 142.NOVARTIS AG: NET SALES,
TABLE 143.NOVARTIS AG: KEY STRATERGIES
TABLE 144.NOVO NORDISK: COMPANY SNAPSHOT
TABLE 145.NOVO NORDISK: OPERATING SEGMENTS
TABLE 146.NOVO NORDISK: PRODUCT PORTFOLIO
TABLE 147.NOVO NORDISK: NET SALES,
TABLE 148.NOVO NORDISK: KEY STRATERGIES
TABLE 149.VIFOR PHARMA: COMPANY SNAPSHOT
TABLE 150.VIFOR PHARMA: OPERATING SEGMENTS
TABLE 151.VIFOR PHARMA: PRODUCT PORTFOLIO
TABLE 152.VIFOR PHARMA: NET SALES,
TABLE 153.VIFOR PHARMA: KEY STRATERGIES
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
